Literature DB >> 34059058

Serial markers of coagulation and inflammation and the occurrence of clinical pulmonary thromboembolism in mechanically ventilated patients with SARS-CoV-2 infection; the prospective Maastricht intensive care COVID cohort.

Mark M G Mulder1, LIoyd Brandts2, Renée A G Brüggemann3, Marcel Koelmann4, Alexander S Streng5, Renske H Olie3,6,7, Hester A Gietema8,9, Henri M H Spronk6,7, Iwan C C van der Horst4,7, Jan-Willem E M Sels4,10, Joachim E Wildberger7,8, Sander M J van Kuijk2, Ronny M Schnabel4, Hugo Ten Cate3,6,7, Yvonne M C Henskens5,7, Bas C T van Bussel4,11.   

Abstract

BACKGROUND: The incidence of pulmonary thromboembolism is high in SARS-CoV-2 patients admitted to the Intensive Care. Elevated biomarkers of coagulation (fibrinogen and D-dimer) and inflammation (c-reactive protein (CRP) and ferritin) are associated with poor outcome in SARS-CoV-2. Whether the time-course of fibrinogen, D-dimer, CRP and ferritin is associated with the occurrence of pulmonary thromboembolism in SARS-CoV-2 patients is unknown. We hypothesise that patients on mechanical ventilation with SARS-CoV-2 infection and clinical pulmonary thromboembolism have lower concentrations of fibrinogen and higher D-dimer, CRP, and ferritin concentrations over time compared to patients without a clinical pulmonary thromboembolism.
METHODS: In a prospective study, fibrinogen, D-dimer, CRP and ferritin were measured daily. Clinical suspected pulmonary thromboembolism was either confirmed or excluded based on computed tomography pulmonary angiography (CTPA) or by transthoracic ultrasound (TTU) (i.e., right-sided cardiac thrombus). In addition, patients who received therapy with recombinant tissue plasminogen activator were included when clinical instability in suspected pulmonary thromboembolism did not allow CTPA. Serial data were analysed using a mixed-effects linear regression model, and models were adjusted for known risk factors (age, sex, APACHE-II score, body mass index), biomarkers of coagulation and inflammation, and anticoagulants.
RESULTS: Thirty-one patients were considered to suffer from pulmonary thromboembolism ((positive CTPA (n = 27), TTU positive (n = 1), therapy with recombinant tissue plasminogen activator (n = 3)), and eight patients with negative CTPA were included. After adjustment for known risk factors and anticoagulants, patients with, compared to those without, clinical pulmonary thromboembolism had lower average fibrinogen concentration of - 0.9 g/L (95% CI: - 1.6 - - 0.1) and lower average ferritin concentration of - 1045 μg/L (95% CI: - 1983 - - 106) over time. D-dimer and CRP average concentration did not significantly differ, 561 μg/L (- 6212-7334) and 27 mg/L (- 32-86) respectively. Ferritin lost statistical significance, both in sensitivity analysis and after adjustment for fibrinogen and D-dimer.
CONCLUSION: Lower average concentrations of fibrinogen over time were associated with the presence of clinical pulmonary thromboembolism in patients at the Intensive Care, whereas D-dimer, CRP and ferritin were not. Lower concentrations over time may indicate the consumption of fibrinogen related to thrombus formation in the pulmonary vessels.

Entities:  

Keywords:  C-reactive protein; COVID-19; Coagulation; D-dimer; Fibrinogen; Intensive care; Pulmonary embolism; Pulmonary thrombosis; SARS-CoV-2

Year:  2021        PMID: 34059058     DOI: 10.1186/s12959-021-00286-7

Source DB:  PubMed          Journal:  Thromb J        ISSN: 1477-9560


  60 in total

1.  Pulmonary Embolism in Patients With COVID-19: Awareness of an Increased Prevalence.

Authors:  Julien Poissy; Julien Goutay; Morgan Caplan; Erika Parmentier; Thibault Duburcq; Fanny Lassalle; Emmanuelle Jeanpierre; Antoine Rauch; Julien Labreuche; Sophie Susen
Journal:  Circulation       Date:  2020-04-24       Impact factor: 29.690

2.  Incidence of venous thromboembolism in hospitalized patients with COVID-19.

Authors:  Saskia Middeldorp; Michiel Coppens; Thijs F van Haaps; Merijn Foppen; Alexander P Vlaar; Marcella C A Müller; Catherine C S Bouman; Ludo F M Beenen; Ruud S Kootte; Jarom Heijmans; Loek P Smits; Peter I Bonta; Nick van Es
Journal:  J Thromb Haemost       Date:  2020-07-27       Impact factor: 5.824

3.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis.

Authors:  F A Klok; M J H A Kruip; N J M van der Meer; M S Arbous; D Gommers; K M Kant; F H J Kaptein; J van Paassen; M A M Stals; M V Huisman; H Endeman
Journal:  Thromb Res       Date:  2020-04-30       Impact factor: 3.944

4.  COVID-19: a novel coronavirus and a novel challenge for critical care.

Authors:  Yaseen M Arabi; Srinivas Murthy; Steve Webb
Journal:  Intensive Care Med       Date:  2020-03-03       Impact factor: 17.440

5.  Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19.

Authors:  Matthias H Busch; Sjoerd A M E G Timmermans; Chris P Reutelingsperger; Pieter van Paassen; Magdolna Nagy; Mayken Visser; Joram Huckriede; Joop P Aendekerk; Femke de Vries; Judith Potjewijd; Borefore Jallah; Renée Ysermans; Astrid M L Oude Lashof; Paul H Breedveld; Marcel C G van de Poll; Iwan C C van de Horst; Bas C T van Bussel; Ruud O M F I H Theunissen; Henri M H Spronk; Jan G M C Damoiseaux; Hugo Ten Cate; Gerry A F Nicolaes
Journal:  Circulation       Date:  2020-09-18       Impact factor: 29.690

6.  Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis.

Authors:  Bilian Yu; Xin Li; Jin Chen; Mingqi Ouyang; Hong Zhang; Xinge Zhao; Liang Tang; Qin Luo; Min Xu; Lizhen Yang; Guxiang Huang; Xianling Liu; Jianjun Tang
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 5.221

7.  COVID-19 Does Not Lead to a "Typical" Acute Respiratory Distress Syndrome.

Authors:  Luciano Gattinoni; Silvia Coppola; Massimo Cressoni; Mattia Busana; Sandra Rossi; Davide Chiumello
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

8.  Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China.

Authors:  J Zhang; X Wang; X Jia; J Li; K Hu; G Chen; J Wei; Z Gong; C Zhou; H Yu; M Yu; H Lei; F Cheng; B Zhang; Y Xu; G Wang; W Dong
Journal:  Clin Microbiol Infect       Date:  2020-04-15       Impact factor: 8.067

9.  COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.

Authors:  Hanny Al-Samkari; Rebecca S Karp Leaf; Walter H Dzik; Jonathan C T Carlson; Annemarie E Fogerty; Anem Waheed; Katayoon Goodarzi; Pavan K Bendapudi; Larissa Bornikova; Shruti Gupta; David E Leaf; David J Kuter; Rachel P Rosovsky
Journal:  Blood       Date:  2020-07-23       Impact factor: 25.476

10.  Pulmonary embolism in COVID-19 patients: a French multicentre cohort study.

Authors:  Charles Fauvel; Orianne Weizman; Antonin Trimaille; Delphine Mika; Thibaut Pommier; Nathalie Pace; Amine Douair; Eva Barbin; Antoine Fraix; Océane Bouchot; Othmane Benmansour; Guillaume Godeau; Yasmine Mecheri; Romane Lebourdon; Cédric Yvorel; Michael Massin; Tiphaine Leblon; Chaima Chabbi; Erwan Cugney; Léa Benabou; Matthieu Aubry; Camille Chan; Ines Boufoula; Clement Barnaud; Léa Bothorel; Baptiste Duceau; Willy Sutter; Victor Waldmann; Guillaume Bonnet; Ariel Cohen; Théo Pezel
Journal:  Eur Heart J       Date:  2020-07-01       Impact factor: 29.983

View more
  4 in total

1.  Hemostasis and fibrinolysis in COVID-19 survivors 6 months after intensive care unit discharge.

Authors:  Anne-Marije Hulshof; Dionne C W Braeken; Chahinda Ghossein-Doha; Susanne van Santen; Jan-Willem E M Sels; Gerhardus J A J M Kuiper; Iwan C C van der Horst; Hugo Ten Cate; Bas C T van Bussel; Renske H Olie; Yvonne M C Henskens
Journal:  Res Pract Thromb Haemost       Date:  2021-09-24

Review 2.  Effects of β-Blockers on the Sympathetic and Cytokines Storms in Covid-19.

Authors:  Hayder M Al-Kuraishy; Ali Ismail Al-Gareeb; Gomaa Mostafa-Hedeab; Keneth Iceland Kasozi; Gerald Zirintunda; Akhmed Aslam; Mamdouh Allahyani; Susan Christina Welburn; Gaber El-Saber Batiha
Journal:  Front Immunol       Date:  2021-11-11       Impact factor: 7.561

3.  Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers.

Authors:  Tarek Owaidah; Khalid Maghrabi; Feras Alfraih; Alfadil Haroon; Khawar Siddiqui; Randa Alnounou; Hadeel AlOtair; Fatmah S Alqahtany; Mohannad Maghrabi; Mustafa Owaidah; Khalid AlSaleh
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

Review 4.  COVID-19 Coagulopathy: From Pathogenesis to Treatment.

Authors:  Teba Alnima; Mark M G Mulder; Bas C T van Bussel; Hugo Ten Cate
Journal:  Acta Haematol       Date:  2022-02-08       Impact factor: 3.068

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.